Wegovy typically costs more due to its packaging, single-dose pen design, and higher prescribed dose
Reviews published in 2024 and 2025 also note growing interest in GLP-1 medications across rheumatology, especially for inflammatory arthritis and psoriasis
I outline a way to play the picks and shovels of this issue, but it is also indicative of the fact that there is significant demand and further impact to be had for this theme - simply put, not enough people are on it yet
As a result, the peptide may induce acromegaly, causing irreversible changes to the physical structure of the body, most notably in the face [17]
Patients with chronic kidney disease, cardiovascular diseases, and those with obesity related complications such as moderate to severe obstructive sleep apnea (OSA) should not use microdoses of GLP-1 medications
10.1038/s41563-024-01933-w Nat Mater